BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 25541967)

  • 1. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection.
    Wang W; Ye C; Liu J; Zhang D; Kimata JT; Zhou P
    PLoS One; 2014; 9(12):e115987. PubMed ID: 25541967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
    Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
    J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
    Yu S; Yao Y; Xiao H; Li J; Liu Q; Yang Y; Adah D; Lu J; Zhao S; Qin L; Chen X
    Hum Gene Ther; 2018 Jan; 29(1):51-67. PubMed ID: 28599597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Efficiency for Biallelic Mutations of the
    Lin D; Scheller SH; Robinson MM; Izadpanah R; Alt EU; Braun SE
    CRISPR J; 2021 Feb; 4(1):92-103. PubMed ID: 33616448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lentivirus pre-packed with Cas9 protein for safer gene editing.
    Choi JG; Dang Y; Abraham S; Ma H; Zhang J; Guo H; Cai Y; Mikkelsen JG; Wu H; Shankar P; Manjunath N
    Gene Ther; 2016 Jul; 23(7):627-33. PubMed ID: 27052803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR5 editing by Staphylococcus aureus Cas9 in human primary CD4
    Xiao Q; Chen S; Wang Q; Liu Z; Liu S; Deng H; Hou W; Wu D; Xiong Y; Li J; Guo D
    Retrovirology; 2019 Jun; 16(1):15. PubMed ID: 31186067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
    Bai J; Rossi J; Akkina R
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection.
    Anderson J; Akkina R
    Retrovirology; 2005 Aug; 2():53. PubMed ID: 16109172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of an HIV-1-resistant immune system with CD34(+) hematopoietic stem cells transduced with a triple-combination anti-HIV lentiviral vector.
    Walker JE; Chen RX; McGee J; Nacey C; Pollard RB; Abedi M; Bauer G; Nolta JA; Anderson JS
    J Virol; 2012 May; 86(10):5719-29. PubMed ID: 22398281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome editing of CCR5 by AsCpf1 renders CD4
    Liu Z; Liang J; Chen S; Wang K; Liu X; Liu B; Xia Y; Guo M; Zhang X; Sun G; Tian G
    Cell Biosci; 2020; 10():85. PubMed ID: 32670545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery.
    Swan CH; Bühler B; Steinberger P; Tschan MP; Barbas CF; Torbett BE
    Gene Ther; 2006 Oct; 13(20):1480-92. PubMed ID: 16738691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4
    Liu Z; Chen S; Jin X; Wang Q; Yang K; Li C; Xiao Q; Hou P; Liu S; Wu S; Hou W; Xiong Y; Kong C; Zhao X; Wu L; Li C; Sun G; Guo D
    Cell Biosci; 2017; 7():47. PubMed ID: 28904745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice.
    Ye C; Wang W; Cheng L; Li G; Wen M; Wang Q; Zhang Q; Li D; Zhou P; Su L
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27881659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs.
    Li MJ; Bauer G; Michienzi A; Yee JK; Lee NS; Kim J; Li S; Castanotto D; Zaia J; Rossi JJ
    Mol Ther; 2003 Aug; 8(2):196-206. PubMed ID: 12907142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Protection of Lymphocytes Against HIV using Lentivirus Vector Carrying a Combination of TRIM5α-HRH Genes and microRNA Against CCR5].
    Omelchenko DO; Glazkova DV; Bogoslovskaya EV; Urusov FA; Zhogina YA; Tsyganova GM; Shipulin GA
    Mol Biol (Mosk); 2018; 52(2):294-305. PubMed ID: 29695698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific transduction of HIV-susceptible cells for CCR5 knockdown and resistance to HIV infection: a novel method for targeted gene therapy and intracellular immunization.
    Anderson JS; Walker J; Nolta JA; Bauer G
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):152-61. PubMed ID: 19593160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases.
    Cai Y; Bak RO; Mikkelsen JG
    Elife; 2014 Apr; 3():e01911. PubMed ID: 24843011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of human immunodeficiency virus-1 entry using vectors expressing a multimeric hammerhead ribozyme targeting the CCR5 mRNA.
    Nazari R; Ma XZ; Joshi S
    J Gen Virol; 2008 Sep; 89(Pt 9):2252-2261. PubMed ID: 18753234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. G protein-dependent CCR5 signaling is not required for efficient infection of primary T lymphocytes and macrophages by R5 human immunodeficiency virus type 1 isolates.
    Amara A; Vidy A; Boulla G; Mollier K; Garcia-Perez J; Alcamí J; Blanpain C; Parmentier M; Virelizier JL; Charneau P; Arenzana-Seisdedos F
    J Virol; 2003 Feb; 77(4):2550-8. PubMed ID: 12551993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter.
    Kamata M; Liu S; Liang M; Nagaoka Y; Chen IS
    Hum Gene Ther; 2010 Nov; 21(11):1555-67. PubMed ID: 20524893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.